News

Details

Published: 04 December 2019

• portfolio-news

ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta (γδ)T cells in a range of cancer indications and a portfolio of novel immunotherapies for the treatment of cancer and autoimmune diseases, announced today the closing of a $53 million (€48 million) Series B financing round. The proceeds of the Series B will be used to fund the initial clinical trial for ImCheck’s first-in-class monoclonal antibody ICT01, to further expand the company’s broad pipeline of immunomodulators targeting the butyrophilins super-family and to bring additional immuno-oncology antibody programs into the clinic. 

Details

Published: 07 November 2019

• portfolio-news

eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, today announced the successful completion of a $100 million Series B financing. The financing was led by Fresenius Medical Care Ventures, with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors including, but not limited to, ARCH Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures all participated. 

Details

Published: 25 October 2019

• portfolio-news

UroMems has received the 2019 Prix Galien USA Med’Start-Up Award for its collaboration with the Mayo Clinic to design a clinical study for a novel medical device to treat patients with stress urinary incontinence (SUI). The UroMems eAUS device, protected by over 70 patents, is based on the latest technological advances in the field of embedded intelligent software and micro-technologies. It addresses the significant unmet need for a safe, effective, reliable, and seamless solution to treat SUI.